Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
metformin + ethinylestradiol + drospirenone
- Development stage
- Preclinical
- Lead developer
- Bayer
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination therapy consisting of metformin (an insulin sensitizer), ethinylestradiol and drospirenone (components of oral contraceptives). This combination is primarily used in the treatment of polycystic ovary syndrome (PCOS), addressing insulin resistance, hormonal imbalance, and associated symptoms like endothelial dysfunction, hyperandrogenism, and metabolic abnormalities.
- Brand names
- metformin + Yasmin
- Other names
- metformin + drospirenone/ethinyl estradiol
02
Targets
AR (Adrenergic receptors)ER (Estrogen receptor)FSHR (Follicle-stimulating hormone receptor)INSR (Insulin receptor)LHCGR (Luteinizing hormone/choriogonadotropin receptor)MR (Mineralocorticoid receptor)PR (Progesterone receptor)LH (Procollagen-lysine, 2-oxoglutarate 5-dioxygenase 1)
Beyond the preview
Go deeper on metformin + ethinylestradiol + drospirenone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on metformin + ethinylestradiol + drospirenone.